The association between metabolic syndrome (MetS) and the risk of osteoarthritis (OA).
Sanofi shelves four assets, including mid-stage dwarfism candidate
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies. The French pharma deprioritized a Phase 2 drug